Shop by goal

Popular compounds

Research resources

Recently viewed

How-to guides

Is BPC-157 FDA Approved? The 2026 Regulatory Status, Explained

Short answer: no. BPC-157 is not an FDA-approved drug. It has never completed a New Drug Application or the Phase III trials that approval requires, and it is supplied strictly as a research-use-only compound, not for human consumption. BPC-157 is on the FDA’s July 23, 2026 compounding advisory committee agenda — but that is a review of possible 503A Bulks List inclusion, which is not the same as drug approval.

“Is BPC-157 FDA approved?” is one of the most common questions about the compound, and the honest answer is short: no, it is not. But the longer answer is worth understanding, because the regulatory picture is more nuanced than a simple yes/no — and it is about to get more attention thanks to a formal FDA review scheduled for July 2026.

What “FDA approved” actually means

FDA approval is the highest standard of clinical evidence in the world. For a drug to be FDA-approved, its sponsor must submit a New Drug Application (NDA) backed by a full programme of clinical trials — typically Phase I (safety), Phase II (efficacy signal) and Phase III (large-scale confirmation) — along with manufacturing controls and a characterised safety profile. Only after the FDA reviews that evidence and agrees the drug is safe and effective for a specific indication does it grant marketing approval.

BPC-157 has not been through that process. There is no approved NDA for it, and there are no completed Phase III trials. For context on which peptides have cleared that bar, see our guide to the FDA peptide approval pipeline.

Is BPC-157 FDA approved? The current status

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a body protective compound first described in human gastric juice. It is widely discussed in tissue-repair, gut-protection and inflammatory-signalling research, and it has a substantial pre-clinical (animal-study) literature behind it. But pre-clinical interest is not approval. As of 2026, BPC-157 remains a research compound : supplied to laboratories as a reagent, labelled research use only, not for human consumption. Our neutral BPC-157 research guide covers the mechanism and the human-trial gap in detail.

The distinction that trips people up. “Not FDA approved” does not mean “illegal to study” or “banned.” It means the compound has not been authorised as a medicine for human use. Research-grade material exists in a separate category — laboratory reagents — and the legal line is determined by how a compound is marketed and used, not by the molecule alone.

The July 2026 FDA review: still not approval

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157 bulk drug substances (free base and acetate) for potential inclusion on the 503A Bulks List , with ulcerative colitis listed as the evaluated use. The 503A Bulks List is relevant to traditional pharmacy compounding — the preparation of medications by licensed pharmacists or physicians for specific patient needs — not to mass-market drug approval.

This means even the upcoming review is about a compounding question, not an approval question. A recommendation for inclusion would not make BPC-157 an FDA-approved medicine. We break down the meeting in full in our FDA peptide review 2026 overview and our dedicated BPC-157 and TB-500 review.

Are TB-500, Semax and Epitalon FDA approved?

No. The same answer applies to the other compounds people often ask about alongside BPC-157:

  • TB-500 — not FDA approved; a research compound discussed in thymosin beta-4 and wound-healing research.
  • Semax — not FDA approved; a research compound discussed in neurological research (approved as a medicine in some other countries, but not by the FDA).
  • Epitalon — not FDA approved; a research compound discussed in longevity and sleep-related research.
  • All four are listed for the FDA’s July 2026 compounding discussion, but none are FDA-approved drugs. The neuro-longevity trio is covered in our Semax, Epitalon and DSIP review.

    Why BPC-157 isn’t approved (yet)

    Most of the BPC-157 evidence base is pre-clinical — animal and laboratory studies — rather than the large, controlled human trials that approval demands. There are also practical reasons the compound has not entered the approval pipeline: it is a relatively small, hard-to-patent molecule, and much of the research interest has stayed in academic and international settings rather than industry-funded trial programmes. Regulators have also raised characterisation, impurity and safety-data questions that an approval pathway would need to resolve. None of that is a verdict on the science; it simply reflects that BPC-157 has not been taken through the formal evidence process.

    What this means if you research BPC-157

    Because BPC-157 is not approved, responsible suppliers position it for laboratory research use only, not for human consumption, and back it with batch-specific testing. When evaluating any research compound, the documentation matters more than the marketing: look for a Certificate of Analysis confirming identity and purity, and treat any “FDA-approved BPC-157” claim as a red flag — no such approval exists.

    Frequently Asked Questions

    Is BPC-157 FDA approved? No. It is not an FDA-approved drug and has not completed a New Drug Application. It is supplied as a research-use-only compound, not for human consumption.

    Will the July 2026 meeting approve BPC-157? No. That meeting concerns possible 503A Bulks List inclusion (pharmacy compounding), which is a different process from drug approval. A recommendation there would not be an approval.

    Is BPC-157 legal? It depends on use and labelling. Research-grade BPC-157 is supplied to labs as a reagent; selling or labelling it for human use is what creates regulatory exposure. See our explainer on whether peptides are legal.

    Related Reading

  • Is BPC-157 Banned? What the FDA Has and Hasn’t Done
  • BPC-157: A Research Guide to the Body Protective Compound
  • FDA Peptide Review 2026: The Full Overview
  • Peptides & the FDA: The Approval Pipeline, Explained
  • The 2023 FDA Peptide Compounding Decision
  • Browse all peptide research guides
  • Source: the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting agenda. External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.

    From the Lab - Peptides on LinkedIn & Facebook

    Lab-Verified Research Compounds

    New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.

    At New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.

    Research-grade · >99% HPLC purity · COA per lot

    Buy BPC-157 from New-U Research Compounds

    Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

    Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

    Shop

  • All Peptides
  • Fat-Loss Peptides
  • Skin & Anti-Aging
  • Stacks & Protocols
  • Compare Vials
  • Peptide 101
  • Learn

  • Research Blog
  • How-To Guides
  • Certificates of Analysis
  • Community Forum
  • Company

  • About Us
  • Contact
  • FAQ
  • Affiliate Program
  • VIP Club
  • Support

  • Shipping & Delivery
  • Pay with Crypto
  • Live Crypto Prices
  • Refund Policy
  • Privacy
  • Terms
  • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • PayPal
  • Crypto
  • Cash App
  • Credit Card
  • SEPA
  • Shop by Compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Retatrutide
  • Semaglutide
  • Tirzepatide
  • CJC-1295 (without DAC)
  • View all compounds →
  • Shop by Goal

  • Fat Loss
  • Growth Hormone
  • Muscle Growth
  • Tissue Repair
  • Recovery
  • Anti-Aging
  • Cognitive
  • Accessories
  • Ships worldwide

  • United Kingdom
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • USA
  • Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    © 2026 New-U Research Compounds · new-u.io · @new.u.io

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.